Bicara Therapeutics Inc.
BCAX
$14.81
$0.271.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.77M | 15.14M | 12.97M | 11.12M | 9.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.39M | 69.44M | 58.34M | 49.12M | 39.89M |
| Operating Income | -82.39M | -69.44M | -58.34M | -49.12M | -39.89M |
| Income Before Tax | -67.81M | -59.47M | -64.84M | -58.41M | -51.98M |
| Income Tax Expenses | 187.00K | 6.00K | 6.00K | 5.50K | 5.00K |
| Earnings from Continuing Operations | -68.00 | -59.48 | -64.84 | -58.41 | -51.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.00M | -59.48M | -64.84M | -58.41M | -51.99M |
| EBIT | -82.39M | -69.44M | -58.34M | -49.12M | -39.89M |
| EBITDA | -82.33M | -69.38M | -58.30M | -49.08M | -39.87M |
| EPS Basic | -40.18 | -59.54 | -96.16 | -92.36 | -88.55 |
| Normalized Basic EPS | -25.11 | -37.20 | -60.10 | -57.72 | -55.34 |
| EPS Diluted | -40.18 | -59.54 | -96.16 | -92.36 | -88.55 |
| Normalized Diluted EPS | -25.11 | -37.20 | -60.10 | -57.72 | -55.34 |
| Average Basic Shares Outstanding | 66.87M | 13.08M | 2.78M | 2.55M | 2.32M |
| Average Diluted Shares Outstanding | 66.87M | 13.08M | 2.78M | 2.55M | 2.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |